Clinical Trials Logo

Clinical Trial Summary

This is a multi center, phase I pilot study of sequential ONCOS-102 and pembrolizumab in patients with advanced or unresectable melanoma progressing after PD1 blockade. The primary objective of the study is to determine the safety of sequential treatment with ONCOS-102 followed by pembrolizumab. The protocol aims to enroll patients into two cohorts: Part I: up to 12 patients will receive sequential treatment with ONCOS-102 followed by pembrolizumab. Part II: up to 12 patients will receive an initial treatment phase with ONCOS-102 followed by a treatment phase with ONCOS-102 in combination with pembrolizumab.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Advanced or Unresectable Melanoma Progressing After PD1 Blockade
  • Melanoma

NCT number NCT03003676
Study type Interventional
Source Targovax ASA
Contact
Status Active, not recruiting
Phase Phase 1
Start date December 2016